NCIt definition : A preparation of human autologous T-lymphocytes that are genetically modified to express
a T-cell receptor (TCR) specific for the human cancer-testis antigen NY-ESO-1 and
a dominant negative (dn) form of transforming growth factor-beta (TGF-beta; TGFb)
receptor (dnTGF-BRII), with potential immunostimulating and antineoplastic activities.
Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction
into the patient, the autologous anti-NY-ESO-1 TCR/dnTGF-BRII-expressing T-cells GSK3845097
recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific
cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1,
a tumor-associated antigen (TAA), is found in normal testis and on the surface of
various tumor cell types. The inclusion of dnTGF-BRII blocks the signaling of the
immunosuppressive cytokine TGFb in the tumor microenvironment (TME) and makes the
GSK3845097 T-cells resistant to TGFb. TGFb negatively regulates T-cell proliferation
and activation and plays a key role in tumor immune suppression.;